Barclays analyst Carter Gould raised the firm’s price target on Pfizer to $30 from $28 and keeps an Equal Weight rating on the shares as part of a Q2 earnings preview for the U.S. biopharmaceutical space. The analyst believes Pfizer (PFE), Eli Lilly (LLY) and Merck (MRK) “are set up for compelling updates,” while Travere Therapeutics’ (TVTX) momentum should continue into the FDA action date.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- ISRG, PFE, or DXCM: Which Healthcare Stock Could Generate the Highest Returns?
- FDA to evaluate potential risk of neural tube birth defects with dolutegravir
- Pfizer Enhances Board with Cyrus Taraporevala’s Appointment
- Pfizer appoints Cyrus Taraporevala to board of directors
- GSK, Pfizer under pressure after CDC narrows RSV shots age recommendation